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Abstract: Chronic infection by hepatitis C virus (HCV) can lead to severe liver disease 
and is a global healthcare problem. The liver is highly metabolically active and one of its 
key functions is to control the balance of lipid throughout the body. A number of 
pathologies have been linked to the impact of HCV infection on liver metabolism. 
However, there is also growing evidence that hepatic metabolic processes contribute to the 
HCV life cycle. This review summarizes the relationship between lipid metabolism and 
key stages in the production of infectious HCV. 
Keywords: hepatitis C virus; HCV; lipid metabolism; lipid droplets; fatty acid biosynthesis; 
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1. Introduction 
1.1. HCV epidemiology and outcomes of HCV infection 
It is predicted that 2.2% of the world’s population has been infected with hepatitis C virus (HCV), 
an estimate that equates to approximately 130 million people [1,2]. Infection typically occurs through 
percutaneous exposure to infected blood. Acute infection is often symptom-free although 20 to 30% of 
infected persons do develop jaundice [3]. The incubation period for acute infection is thought to 
continue for between seven to eight weeks [4] and thereafter, up to 85% of individuals develop a 
chronic infection. Over a period of decades, chronic infection can lead to severe liver disease [5], 
including decompensated cirrhosis and hepatocellular carcinoma, which are end-stage conditions [6]. 
1.2. Molecular characteristics of HCV 
HCV has been classified as a Hepacivirus within the Flaviviridae family [7,8] and separated into six 
genotypes or clades (numbered 1-6) [7-9]. Some genotypes have a restricted geographical distribution 
(genotypes 4-6) while others (genotypes 1-3) are more broadly disseminated. Although all of the 
genotypes can establish chronic infection, there are specific properties associated with particular 
genotypes. For example, steatosis is more prevalent in genotype 3 infections and there is evidence for 
a direct role for a viral factor in the development of this pathology [10,11]. Moreover, strains from 
genotypes 1 and 4 respond less well to pegylated alpha-interferon (IFN-) and ribavirin combination 
therapy as compared to genotype 2 and 3 strains [12]. 
HCV has a positive-sense, single-stranded RNA genome of some 9.6 kilobases that encodes a 
polyprotein of about 3000 amino acids [13,14]. The open reading frame for the polyprotein is flanked 
by 5’ and 3’ untranslated regions (UTRs), which contain elements that regulate translation and 
replication. The polyprotein is generated by the host cell translation machinery and cleaved co- and 
post-translationally by viral and cellular proteases to yield the mature viral proteins. The N-terminal 
segment of the polyprotein encodes the structural components of the virus, which consist of core 
protein and two glycoproteins termed E1 and E2. Core forms the capsid shell into which the virus 
genome is packaged while the glycoproteins are considered to locate to the lipid envelope surrounding 
the capsid. However, it should be emphasized that the structure and composition of HCV virions is 
poorly defined since virus isolated from infectious serum is associated with lipoprotein [15,16]. A 
small protein called p7, which resides immediately downstream from E2, is required for virus 
assembly [17,18] although it is not known whether it is also a component of virions.  
The C-terminal component of the polyprotein contains non-structural proteins (NS2, NS3, NS4A, 
NS4B, NS5A and NS5B) that provide functions necessary for synthesis of viral RNA [19,20]; several 
of these proteins also participate in assembly of infectious particles [17,21-25]. Expression of a 
polyprotein encoding NS3-NS5B, along with the 5’ and 3’ UTR elements (referred to as sub-genomic 
replicons), is sufficient to initiate and sustain constitutive HCV RNA replication. Viral RNA 
replication occurs at rearranged internal membrane structures known as the membranous web [26]. 
Viewed under the electron microscope, the membranous web is observed as networks of   
membrane-bound vesicles, derived from the ER, and similar in appearance to those observed in 
poliovirus-infected cells [27,28]. Viruses 2010, 2                                       
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2. Cell organelles and metabolic pathways that contribute to HCV infection 
Development of tissue culture systems that support replication of viral RNA and production of 
infectious virions has enabled identification of the cellular processes contributing to these latter phases 
of the HCV life cycle. Accumulating evidence has established critical roles for pathways involving 
lipid biosynthesis and very low density lipoprotein (VLDL) assembly as well as storage organelles, 
called lipid droplets. The following sections outline some of the key characteristics of the 
triacylglycerol and cholesterol ester biosynthesis pathways, stages in VLDL assembly and features of 
lipid droplets to aid understanding of their contribution to the virus life cycle. 
2.1. Fatty acid and cholesterol biosynthesis 
Biosynthesis of fatty acids and cholesterol is of fundamental importance to maintenance of cellular 
homeostasis. Fatty acid synthesis initiates through the irreversible carboxylation of acetyl-CoA by 
acetyl-CoA carboxylase to generate malonyl-CoA (Figure 1A). Thereafter, fatty acid synthase 
performs a cycle of elongation steps, utilizing one acetyl-CoA and seven malonyl-CoA moieties, to 
generate palmitic acid [29]. Fatty acid synthase is a large, homodimer of 552 kDa that catalyses each 
of the sequential reactions [30]. Palmitic acid is then employed as a substrate for further elongation or 
desaturation. Elongation is mediated by a family of elongase enzymes, referred to as ELOVLS 
(Elongation of very-long-chain fatty acids) [31] while the desaturases are responsible for introducing 
double bonds at specific positions in the acyl chain of fatty acids. Mammalian cells express three 
desaturases (9, 6 and 5); the 9-desaturase is commonly referred to as stearoyl-CoA desaturase 
while the 6- and 5-desaturases are termed fatty acid desaturases. Elongases exhibit preferential 
specificity for saturated, mono- and poly-unsaturated fatty acids and hence there is complex interplay 
between the ELOVLS and desaturases.  
Incorporation of fatty acids into triacylglycerols (TAGs), which are major components of the 
hydrophobic core in lipid droplets (see below), begins with the addition of an acyl-CoA ester by  
long-chain acyl-CoA synthetase (ACS; Figure 1A). Thereafter, two fatty acyl-CoAs are used to 
sequentially acylate glycerol-3-phosphate, firstly forming lysophosphatidic acid (catalyzed by 
glycerol-3-phosphate acyltransferase) and then phosphatidic acid (catalyzed by lysophosphatidic acid 
acyltransferase). Phosphatidic acid is converted to diacylglycerol by phosphatidate   
phosphohydrolase-1 before final addition of another fatty acyl-CoA to yield TAG. This final stage in 
the pathway is performed by diacylglycerol acyltransferase (DGAT). Two DGAT enzymes, DGAT1 
and DGAT2, have been identified, which appear to have distinct intracellular roles [32]. It has been 
hypothesized that DGAT1 may be involved in esterification of exogenous fatty acids or the   
re-esterification of fatty acids after their hydrolysis. By contrast, DGAT2 may incorporate 
endogenously synthesized fatty acids into triglycerides. Viruses 2010, 2                                       
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Figure 1. Scheme for triacylglycerol (a) and cholesterol ester synthesis (b). For the 
synthesis of triacylglycerols, note that there is an alternative monoacylglycerol pathway for 
TAG synthesis in addition to the glycerol phosphate pathway shown in a [33]. In addition, 
fatty acids from diet are utilized for production of fatty acyl-CoAs as well as endogenously 
synthesized fatty acids. Abbreviations are as follows: ACAT, acyl-coenzyme A:cholesterol 
transferase; ACC, acetyl-CoA carboxylase; ACS, long-chain acyl-CoA synthetase; DGAT, 
diacylglycerol acyltransferase; FAS, fatty acid synthase; FPP, farnesyl pyrophosphate; 
GPAT, glycerol-3-phosphate acyltransferase; GPP, geranyl pyrophosphate; HMG-CoA, 3-
hydroxy-3-methylglutaryl-CoA; IPP, isopentenyl pyrophosphate; LPAAT, 
lysophosphatidic acid acyltransferase; PPH-1, phosphatidate phosphohydrolase-1. 
 
 
Cholesterol biosynthesis is more complex than the pathway for production of fatty acids and 
involves at least 30 distinct enzymatic reactions. Synthesis can be divided into five major steps   
(Figure 1B). Firstly, HMG-CoA synthase catalyzes a condensation reaction between acetyl-CoA and 
acetoacetyl-CoA to yield 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). The second stage is the Viruses 2010, 2                                       
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production of mevalonic acid from HMG-CoA by HMG-CoA reductase, the rate-limiting step in the 
cholesterol synthesis pathway and the target for statins. Following a combination of phosphorylation 
and decarboxylation reactions, mevalonate gives rise to isopentenyl pyrophosphate (IPP), which is 
then converted to squalene by a series of condensation and reduction reactions. The pathway between 
IPP and squalene includes the production of geranyl pyrophosphate (GPP) and farnesyl pyrophosphate 
(FPP); these intermediates are used not only in the squalene synthesis pathway but also for the 
production of geranylgeranyl pyrophosphate (GGPP), which is a substrate for geranylgeranylation of 
proteins [34]. Conversion of squalene to cholesterol occurs through a complex pathway that includes 
lanosterol as a major intermediate. Subsequent formation of cholesterol esters (CE; Figure 1B) from 
cholesterol and fatty acyl-CoAs is mediated by acyl-coenzyme A:cholesterol transferase (ACAT). Two 
ACAT genes have been identified, ACAT1 and ACAT2, both of which are expressed in hepatocytes 
[35]. Along with TAG, CE is stored in the hydrophobic core of lipid droplets (see below). 
2.2. Characteristics of lipid droplets 
Lipid droplets are cytoplasmic storage organelles that are composed principally of a hydrophobic 
core of TAG and CE. Bounding the hydrophobic core is a monolayer of phospholipid whose 
composition is distinct from that of the rough endoplasmic reticulum (ER) and cholesterol/sphingolipid 
microdomains [36]. The phospholipid layer is coated in a surface layer of proteins, which have a wide 
array of functions including roles in lipid metabolism, intracellular trafficking and signaling [37]. 
Lipid droplets are not a homogeneous population of organelles and can differ in protein composition 
between different cell types and by altering the metabolic state of cells [38]. Indeed, within individual 
cells, it is likely that distinct populations of lipid droplets exist, raising the possibility that there are 
pools of lipid droplets with differing functions. 
2.3. Assembly of VLDL 
VLDLs are released by hepatocytes in the liver and have a similar architecture to lipid droplets in 
that they are composed of a TAG- and CE-rich hydrophobic core that is bounded by a layer of 
phospholipid and protein [39]. The proteins that coat VLDL consist of non-exchangeable 
(apolipoprotein B [apoB]) and exchangeable apoproteins (principally apoCI-III and apoE) [40]. ApoB 
is a long, amphipathic protein of 4536 amino acids [41,42] that is essential for assembly of VLDL. 
Assembly is considered to proceed through two stages of lipidation of apoB. Firstly, apoB is lipidated 
by microsomal transfer protein (MTP), which is an ER lumenal protein. MTP is a heterodimer of two 
proteins with molecular weights of 88 and 58 kDa, the smaller of which is protein disulfide isomerase 
[43]. MTP both binds to apoB and facilitates transfer of lipid to the protein during its translation, 
ultimately leading to the production of a precursor VLDL (pre-VLDL) particle that is poorly lipidated 
[44]. Bulk addition of lipid constitutes the second stage in VLDL assembly, generating a mature, 
secretion-competent particle. However, the intracellular location and processes involved in lipidation 
of pre-VLDL are not well understood. It appears that the further addition of lipid to pre-VLDL does 
not rely on either MTP or the need for ongoing TAG synthesis [45,46]. Indeed, all the available 
evidence indicates that lipid droplets supply the lipid that is needed to convert pre-VLDL to a mature 
particle [47]. By way of example, increasing the expression levels of adipocyte differentiation-related Viruses 2010, 2                                       
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protein (ADRP), the major protein on the surface of lipid droplets in hepatocyte-derived cells [48], 
stimulates accumulation of droplets and reduces secretion of VLDL from rat hepatocytes [49].  
Mobilization of lipid from droplets relies on several enzymes involved in TAG and cholesterol 
metabolism. Transfer of TAG and CE from a lipid droplet to pre-VLDL seems to require de-
esterification followed by re-esterification. A number of reports have investigated involvement of 
several enzymes including triacylglycerol hydrolase (TGH), DGAT1, and ACAT2. TGH converts 
TAG to acylglycerols and fatty acids [50]. Expression of TGH in mice and rat hepatoma cells gives a 
modest rise in triglyceride secretion [50,51]. As stated above, DGAT1 catalyzes the last stage in the 
synthesis of TAG and there is evidence to suggest that the enzyme participates in hepatic VLDL 
assembly [52]. By contrast, DGAT2 appears to direct TAG for lipid storage [52]. ACAT2 plays a 
major contribution to CE formation in the liver and intestine [53,54]. Studies in rat cells have shown 
that overexpression of human DGAT1 and ACAT2 individually leads to increased secretion of VLDL 
[55]. Interestingly, compared to ACAT1, ACAT2 induced higher levels of VLDL secretion, thereby 
providing evidence for its predominant role in CE formation in the liver. However, it should be noted 
that there are conflicting data from overexpression studies in rodents, [for example [56]], which 
illustrates the difficulty with formal demonstration that any individual enzyme can stimulate VLDL 
secretion. 
3. HCV proteins that attach to lipid droplets  
Before the availability of a tissue culture system that produced infectious virus particles, two viral 
proteins, core and NS5A, had been reported to attach to lipid droplets. Recent studies have established 
that these lipid droplet-binding characteristics are vital for virus assembly. Hence, the following 
sections describe some of the essential properties of both proteins, particularly in relation to their 
ability to attach to lipid droplets. 
3.1. Properties of the HCV core protein 
As stated in Section 1.2, core protein forms the capsid within HCV virions. Maturation of core 
requires cleavage by two cellular proteases at a signal peptide between core and the adjacent E1 
glycoprotein [57-59]. The first proteolytic event is performed by signal peptidase, which cuts between 
amino acids 191 and 192 in the ER lumen, thereby generating an immature form of core and the  
N-terminus of E1. The fully processed form of core requires further proteolysis by signal peptide 
peptidase within the signal peptide sequence at the C-terminus of immature core. The precise location 
of signal peptide peptidase cleavage remains unclear, but analysis of core protein isolated from cells 
indicates that its C-terminus lies between amino acids 177 and 182 [57,60].  
Mature core can be separated into two domains, termed D1 and D2 [61]. D1 consists of the   
N-terminal 117 amino acids of core and contains a high proportion of positively-charged residues. D1 
is thought to interact with viral RNA but also associates with a variety of cellular components [62]. D2 
begins at amino acid position 118 and terminates at the C-terminus of the protein. This domain is 
responsible for directing core to lipid droplets and does not require sequences in D1 for attachment. 
Indeed, D1 can be replaced by a heterologous protein with no disruption to lipid droplet-targeting by 
D2 [63]. D2 and its membrane-binding characteristics also contribute to folding of the entire core Viruses 2010, 2                                       
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protein [64]. Structural studies on the domain have revealed that it contains two amphipathic -helices 
(Helix I and Helix II) that are separated by a non-structured segment with several hydrophobic 
residues, termed the hydrophobic loop (HL) [63]. Removal of segments from D2 that includes deletion 
of these structural features leads to loss of lipid droplet localization of core. Moreover, mutations at 
individual amino acids on the hydrophobic faces of HI and HII can abolish attachment to droplets. 
Such substitutions can also induce degradation of core by the proteasome [63]. Thus, it has been 
proposed that attachment of D2 to membranous surfaces is critical for folding of the domain, which in 
turn enables folding of the remainder of core, and disruption of membrane binding exposes core to 
cellular degradative processes. 
3.2. Properties of the HCV NS5A protein 
NS5A is a phosphoprotein that is detected in basally phosphorylated (56 kDa) and 
hyperphosphorylated (58 kDa) forms. It is composed of three domains (DI-DIII) that are separated by 
low complexity sequences LCSI (between DI and DII) and LCSII (between DII and DIII), which are 
trypsin-sensitive [65]. Domains DI and DII are essential for HCV RNA replication while recent studies 
have demonstrated that DIII plays a key role in virion assembly [21,24,66-68]. The crystal structure of 
DI suggests that NS5A forms a dimer that contains a groove for binding RNA at the interface between 
the monomers [69]. The N-terminal end of DI also has an amphipathic helix that anchors the protein to 
membranes [70,71]. In contrast to DI, there is no structural information available for either DII or DIII. 
Compared with core protein, NS5A is less readily detected on lipid droplets and is more broadly 
distributed on the ER membrane [72]. There is limited information regarding the motifs that are 
needed for attachment of NS5A to lipid droplets. However, it has been noted that mutation of residues 
between amino acids 99-104 in DI impairs detection of NS5A on droplets [73]. These residues are 
located in a segment of random coil at the junction of two subdomains in DI, which is relatively 
proline-rich. Moreover, mutations in DIII that do not disrupt lipid droplet targeting reduce the extent 
of co-localization between NS5A and core on droplets [21]. Although these data indicate that NS5A 
does not require core for lipid droplet attachment, additional studies are required to identify in greater 
detail the droplet-targeting elements in the protein.  
4. The contribution of fatty acid and cholesterol biosynthesis to HCV RNA replication 
Microarray studies in chimpanzees have indicated that both acute and chronic HCV infection 
correlates with changes in the expression patterns of genes, which have either a direct role in lipid 
metabolism or regulate the fatty acid and cholesterol biosynthesis pathways [74-76] suggesting a link 
between viremia and lipid metabolism. Direct evidence from tissue culture models that lipid 
biosynthesis contributes to replication of the HCV genome emerged from analysis of changes in viral 
RNA mediated by modulators and inhibitors of fatty acid and cholesterol metabolism [76-78]. In the 
cholesterol biosynthesis pathway, there has been particular focus on statins, since these compounds are 
potent inhibitors of HMG-CoA reductase and are widely used as a therapeutic to lower blood 
cholesterol levels. Early studies established that lovastatin reduced HCV RNA levels by more than  
20-fold in cells harboring viral replicons [77,78]. Subsequent comparative analysis of a range of statins 
demonstrated that mevastatin, simvastatin and atorvastatin were more potent inhibitors of HCV RNA Viruses 2010, 2                                       
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replication than lovastatin [79,80]; fluvastatin had either equivalent [79] or greater potency [80] 
compared to lovastatin. Interestingly, in neither of these studies did pravastatin have any effect on viral 
RNA levels, suggesting that inhibition of HCV RNA synthesis may not result solely from effects of 
statins on HMG-CoA reductase [80]. Combining statins with either IFN- or anti-HCV compounds 
enhances reduction in HCV RNA levels and can delay the emergence of resistance mutants in tissue 
culture cells [79,80]. These data provide promise that statins could be combined with the current 
standard treatment regimens to improve response to therapy. However, early clinical trials have given 
equivocal results. Monotherapy with fluvastatin has been reported to give moderate and short-lived 
reductions in viral load [81] while statins apparently improve ALT levels [82] and, in combination 
with IFN- and ribavirin, enhance the rapid virological response [83]. However, other studies report 
no improvement in sustained clearance of virus following use of statins as an adjunct to current 
treatment regimens [83-85]. 
Interestingly, the inhibitory effect of statins on RNA replication in tissue culture cells can be 
alleviated by addition of geranylgeraniol [78] and inducing the accumulation of geranylgeranyl 
intermediates gives higher levels of viral RNA synthesis [77]. These results led to identification of 
FBL2, which is modified by geranylgeranylation (see Section 2.1), as a cellular factor that binds to 
HCV NS5A, thereby promoting HCV RNA synthesis through a mechanism that is, as yet,   
unknown [86]. 
Compared to components engaged in cholesterol metabolism, the role of the fatty acid biosynthesis 
pathway in HCV RNA replication has received somewhat less attention. Inhibition of acetyl-CoA 
carboxylase, which irreversibly converts acetyl CoA to malonyl CoA, gives a three-fold decrease in 
viral RNA replication [77]. Treatment of cells harboring the HCV replicon with cerulenin, a fatty acid 
synthase inhibitor, also yields a modest lowering of HCV RNA levels [76]. In agreement with a 
contribution of fatty acid biosynthesis to RNA replication, the abundance of viral RNA increased upon 
addition of saturated and monounsaturated fatty acids to cells [77]. By contrast, polyunsaturated fatty 
acids (PUFAs; e.g., arachidonic, eicosapentaenoic and docosahexaenoic acids) lowered HCV genome 
synthesis [77,87]. PUFAs can suppress lipogenesis in the liver however impairment of HCV RNA 
replication does not apparently operate by this mechanism [77] but rather through production of lipid 
peroxides from exogenously administered PUFAs [88]. 
5. The contribution of lipid droplets to production of infectious HCV 
5.1. Lipid droplets are associated with HCV-induced membrane rearrangements 
It is widely accepted that the membranous web houses sites of HCV genome synthesis   
(see Section 1.2). In a recent study, a higher percentage of lipid droplets was observed in close 
proximity to modified ER membrane cisternae in Huh-7 cells that contained replicating full-length 
JFH-1 genomes compared to naïve cells [73]. Specifically, rearranged ER membranes appeared to 
partially enclose lipid droplets in a configuration more reminiscent of the convoluted membrane 
structures observed in cells infected with Kunjin virus (a member of the Flaviviridae family) [73,89]. 
Core protein was observed mainly on the periphery of lipid droplets and although some NS5A protein 
was detected on the lipid droplet surface, the majority was distributed at sites distal to droplets [73]. 
Furthermore, 50 nm virus-like particles, which reacted with core- and E2-specific antibodies, were Viruses 2010, 2                                       
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also observed in close proximity to lipid droplet-associated membranes, suggesting infectious HCV 
particles were generated from such a membranous environment [73]. In a separate study, the 
interaction of HCV-like particles with lipid droplets was assessed using three-dimensional 
reconstructions of serial ultrathin electron microscopy sections produced from cells producing HCV 
core protein [90]. The results also supported the notion that budding of virus is initiated from 
membranes closely associated with lipid droplets [90].  
5.2. Virus production is dependent upon recruitment of replication complexes to lipid droplet-
associated membranes 
The precise purpose for attachment of core to lipid droplets remains unknown and is currently an 
active area of study. Historically, the absence of tissue culture systems to propagate HCV meant that 
the mechanisms by which core-coated lipid droplets interacted with ER-resident replication complexes 
to facilitate virion assembly were not amenable to investigation. However, following the discovery that 
HCV strain JFH-1 genotype and chimeras derived from this strain could release infectious particles 
from cells [91-93], it has been established that the NS proteins localize to distinct foci juxtaposed to 
lipid droplets in cells producing progeny virus [21,73,94-96]. These specific lipid droplet-associated 
foci likely represent accumulations of replication complexes since negative-sense HCV RNA and 
virus-specific dsRNA replicative intermediates are detected within the foci [73,94]. Replication 
complexes do not localize to lipid droplet-associated regions of the ER in cells containing subgenomic 
HCV replicons, therefore, lipid droplets are presumably not required for HCV RNA replication per se 
[94]. Blocking attachment of core to lipid droplets in cells containing JFH-1 genomes, through 
mutations in either the D2 domain or the core-E1 signal sequence to impair signal peptide peptidase 
cleavage, prevents detection of HCV-induced dsRNA-containing foci and NS proteins in close 
proximity to lipid droplets [73,97]. Under these circumstances, HCV genome replication appeared 
unaffected but release of infectious virus was impaired [97]. Thus, recruitment of replication 
complexes to lipid droplet-associated regions of the ER membrane is a phenomenon likely required for 
the assembly of infectious virus progeny.  
There are at least two possible mechanisms in operation in HCV-infected cells, which serve to 
localize replication complexes to regions of the ER in close proximity to core-coated lipid droplets. 
The first centers on the capacity of core to induce lipid droplet redistribution [98,99]. In virus-infected 
cells, or cells expressing core protein alone, lipid droplets are redistributed from a diffuse cytoplasmic 
localization to the perinuclear region [98,99]. Lipid droplet redistribution coincides with release of 
infectious virus progeny in cells containing full-length JFH-1 genomes and redistribution is believed to 
be dependent upon the microtubule network [98]. Furthermore, in nocodazole-treated cells in which 
lipid droplet redistribution has been inhibited, virus release is impaired [98]. Aggregation of lipid 
droplets at the perinuclear region increases the level of colocalization observed between core-coated 
lipid droplets and ER-resident replication complexes and may effectively serve to concentrate core at 
sites of replication to increase the likelihood of virus assembly [94,98]. Another mechanism that could 
facilitate the congregation of core-coated lipid droplets and replication complexes involves the HCV-
encoded NS5A protein. NS5A is a component of the HCV replication complex and is essential for 
viral genome replication but its precise function in the HCV life cycle remains unknown [68-71, Viruses 2010, 2                                       
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100-102]. However, several lines of evidence exist to support a role for NS5A in the recruitment of 
replication complexes to core-coated lipid droplets. Firstly, NS5A exhibits an inherent capacity to 
localize to the surface of droplets [72]. Furthermore, variants of NS5A containing mutations in domain 
DI have impaired capacity for lipid droplet-association, and also prevent recruitment of other NS 
proteins and viral RNA to lipid droplets leading to diminished virus production [73]. Deletions in 
domain DIII have also been shown to disrupt the colocalization of NS5A with core-coated lipid 
droplets resulting in the abrogation of infectious particle release [21]. Additionally, DIII facilitates an 
interaction between NS5A and core, suggesting a mechanism whereby NS5A can target replication 
complexes to lipid droplets via a direct interaction with core protein on the droplet surface [103]. One 
other option is that cellular cyclophilins, which share peptidyl-prolyl cis-trans-isomerases activity and 
play an important role in HCV RNA replication [104-106], may influence the mechanism for directing 
replication complexes to core-coated lipid droplets although this possibility has not been tested. Taken 
together, the combined actions of core and NS5A in virus-infected cells likely play pivotal roles in the 
accumulation of replication complexes at lipid droplet-associated regions of the ER membrane.  
5.3. Rationale for targeting replication complexes to lipid droplet-associated regions of the ER 
membrane  
The requirement for replicated genomes to be available at sites of virus assembly to initiate virion 
morphogenesis may serve to explain the close proximity of replication complexes with lipid droplets 
coated with core protein [73,97]. The mechanism for transfer of replicated genomes from replication 
complexes to core on the surface of lipid droplets is unknown, but NS5A has several specific 
biological properties that appear particularly suited to such a role. Firstly, NS5A binds to the 3’ 
positive-sense polypyrimidine tract of HCV genomes with high affinity, a function believed to be 
mediated following the dimerization of the protein, which creates a putative RNA-binding cleft in the 
DI domains of the dimer [69,102,107]. Secondly, replicons encoding defects in NS5A can be rescued 
by trans-complementation with wt replicons suggesting NS5A is able to transfer between individual 
replication complexes [21,108,109]. This finding indicates NS5A may be a more flexible, rather than 
fixed, component of the replication complex, a property suited to a role in the transfer of replicated 
genomes from replication complexes to core at the surface of lipid droplets. Thirdly, NS5A has long 
been known to exist as differentially phosphorylated species in cells replicating HCV RNA [110-112], 
and phosphorylation of NS5A is believed to act as a regulator of events in the HCV life cycle 
[24,66,113]. Indeed, inhibition of NS5A hyperphosphorylation elevates levels of HCV genome 
replication [66,100,114,115]. Recently, it was established that phosphorylation of a serine residue 
located in a casein kinase II consensus motif in the DIII domain of JFH-1 NS5A was required for 
virion production [24]. Abrogating phosphorylation at this site perturbed production of infectious virus 
particles without affecting RNA replication [24]. These findings indicate that hyperphosphorylation of 
NS5A favors the latter stages of the HCV life cycle, perhaps by stimulating genome transfer from 
replication complexes to core-coated lipid droplets by promoting replication complex disassembly at 
lipid droplet-associated regions of the ER. Released genomes would then be captured by core protein 
sequestered on the lipid droplet surface to enable initiation of virion morphogenesis [103,113]. 
Genome transfer may not be the only reason for the close proximity of replication complexes to lipid Viruses 2010, 2                                       
 
 
1205
droplet-associated regions of the ER in virus-infected cells; an unexpected role for NS3 in virion 
morphogenesis at lipid droplets has been recently described [23]. Multiple mutations in NS3 can 
rescue a defect in an early-intermediate step in virus assembly that follows recruitment of NS5A to 
lipid droplet-associated ER regions but precedes the formation of intracellular virus particles [23]. 
Thus, it is possible that interaction of NS3 with a virus- or host-encoded protein at the lipid droplet 
surface may be involved in particle assembly and suggests that additional interactions involving the 
NS proteins, which serve to facilitate virion formation, may be identified in the future.  
5.4. The link between assembly of HCV and VLDL 
There are clear connections between HCV and VLDL assembly since inhibitors of MTP and 
decreasing expression of apoB by siRNA- and shRNA-targeting lowers virion production [116,117]. 
Lowering apoE expression also impairs release of infectious HCV [118,119] although the authors of 
these studies found that reducing apoB did not affect virion production and high levels of MTP 
inhibitors were necessary to block release of virus progeny. Further evidence of a role for apoE in 
virus secretion, which involved interaction with NS5A, has been reported recently [120]. It has been 
proposed that a selection process during assembly may direct nascent virus particles for degradation 
should they not undergo complete maturation that could involve addition of lipids [116]. However, any 
further details as to the mechanisms that operate during virion assembly are not known. With regard to 
lipid droplets, there is conclusive evidence that disabling the ability of core to target lipid droplets 
leads to impairment of infectious virus production [97]. Since lipid droplets do play a key role in 
VLDL assembly, it is reasonable to speculate that they actively participate in the production of virions. 
Indeed, the targeting of core to lipid droplets could represent an entry site for the virus to gain access 
to the VLDL assembly pathway. 
6. The role of extracellular factors involved in lipid metabolism that participate in virus entry 
Aside from intracellular processes that influence HCV RNA replication and virion assembly, 
extracellular components and factors on the plasma membrane, which are engaged in lipid transport, 
also play crucial roles in the entry of secreted, infectious virus into uninfected cells. This topic has 
been recently reviewed [122,123] and is briefly outlined in the following sections. 
6.1. Receptors on the cell surface necessary for virus infection 
The HCV entry pathway requires interaction between virion components, in particular the envelope 
glycoproteins E1 and E2, and several molecules on the cell surface. These include the low-density 
lipoprotein receptor (LDL-R) [124], glycosaminoglycans [125], CD81 [126], SR-BI [127], Claudin-1 
(CLDN-1) [128] and occludin [129]. In the context of lipid transport, two surface receptors, LDL-R 
and SR-BI, are worthy of note.  
LDL-R sequesters cholesterol-containing lipoproteins from the circulation for uptake of cholesterol 
into cells [130]. The receptor primarily binds LDL but it also has high affinity for VLDL particles 
containing multiple copies of apoE. Lipoprotein particles complexed to LDL-R are internalized by 
endocytosis via clathrin-coated pits and then transported to endosomes. The low pH environment in Viruses 2010, 2                                       
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endosomes induces detachment of LDL-R from internalized lipoprotein particles, which are thereafter 
broken down by lysosomes to release cholesterol into the cell. HCV entry can be blocked by 
antibodies against LDL-R and a soluble peptide that encompasses the LDL-binding domain of the 
receptor [124,131]. Moreover, a recent report has demonstrated that reducing the abundance of LDL-R 
lowers infectivity of cell culture-derived virions, supporting the notion that interaction with the 
receptor contributes to productive infection [132]. The virion component that interacts with LDL-R is 
likely to be a cell-derived lipoprotein since antibodies against apoB and apoE disrupt infection 
[118,124,132,133]. 
SR-BI is a scavenger receptor that plays a key role in promoting the exchange of cholesterol 
between cells and lipoprotein particles [134]. The primary ligand for SR-BI is high-density lipoprotein 
(HDL) from which it selectively transfers cholesterol ester by a non-endocytic mechanism that, in 
contrast to cholesterol import by LDL-R, does not require degradation of HDL-associated 
apolipoproteins. SR-BI was initially identified as a potential receptor for HCV entry since it was 
capable of binding to the soluble portion of E2 [127] although direct interaction between SR-BI and 
the viral glycoproteins on infectious particles has not been demonstrated. Antibodies against SR-BI 
and reduced expression of the receptor inhibit HCV infection [135-138], providing confirmatory 
evidence for its contribution to virus entry. 
6.2. Extracellular components that affect virus entry 
As well as receptors expressed on the cell surface, extracellular components determine the 
efficiency of virus infection. For example, HDL, which is the ligand for SR-BI, enhances the process 
of entry through a mechanism that relies on the lipid transfer function of the receptor [135,138,139]. 
By contrast, oxidized LDL, another ligand for SR-BI, is a potent inhibitor of HCV infection [140] and 
VLDL also blocks the entry process [141]. Finally, lipoprotein lipase, the key enzyme involved in 
lipolysis of triglycerides in circulating VLDL, modulates cellular uptake of the virus [133].  
7. Conclusions and future perspectives 
In summary, there is conclusive evidence that the production of infectious virus from HCV-infected 
cells relies on several aspects of lipid metabolism (summarized in Figure 2). However, further studies 
are necessary to improve our understanding at the molecular level of the underlying mechanisms that 
engage metabolic pathways with both HCV RNA replication and virion assembly. In the case of RNA 
replication, the dependence on both fatty acid and cholesterol metabolism may indicate the need for a 
particular lipophilic environment to support genome synthesis. Creating such an environment may rely 
not only on lipid biosynthetic pathways but also factors involved in membrane organization such as 
class III phosphatidylinositol 4-kinase alpha (PI4K-III), which plays a critical role in HCV RNA 
replication [142-144]. Moreover, additional studies into the biology of lipid droplets, and more in-
depth analysis of the molecular requirements for the latter stages in the HCV life cycle, will help 
delineate the exact role for these organelles in the generation of HCV virions. Finally, the reliance of 
HCV upon both lipid biosynthesis and storage raises the distinct possibility that these topics could be 
important for development of new therapies for pharmacological inhibition of HCV morphogenesis. Viruses 2010, 2                                       
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Figure 2. Inhibition of HCV RNA replication and virion assembly by blocking lipid 
biosynthesis and VLDL assembly. HCV RNA replication occurs at the ER membrane in 
specialized sites (the membranous web) that contain replication complexes. HCV core 
associates with cytosolic LDs and its interaction with NS5A at HCV RNA replication sites 
enables engagement of viral genomes with core to initiate virus assembly, possibly 
creating nucleocapids. Assembly is then thought to proceed through unknown processes in 
which the viral envelope glycoproteins (E1 and E2) are added to nucleocapsids and 
combine also with the VLDL assembly pathway to yield lipoviroparticles [121] that are 
released from the cell. Production of virus particles is thought to occur through interaction 
with the VLDL assembly pathway, which is a two-stage process. Firstly, there is initial 
lipidation of translocated apoB by MTP to create a pre-VLDL particle. Bulk 
triacylglycerol from cytosolic LDs is added to pre-VLDL particles through a process that 
is considered to produce lumenal LDs. Additional lipoprotein components are added also 
at this stage (including apoE) to generate mature VLDL. Steps in fatty acid and cholesterol 
biosynthesis and the VLDL assembly pathway that can be impaired thereby blocking HCV 
RNA replication and virion assembly are boxed. Abbreviations are as follows: ACC, 
acetyl-CoA carboxylase; FAS, fatty acid synthase; GGTase 1, geranylgeranyltransferase 1; 
MTP, microsomal transfer protein; PUFAs, polyunsaturated fatty acids. 
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